Clinical value of serum COX-2 in predicting patients′ responses to targeted therapy for advanced NSCLC
10.3969/j.issn.1006-5725.2014.23.023
- VernacularTitle:血清环氧化酶－2在靶向治疗晚期非小细胞肺癌中的预测价值
- Author:
Huanhuan LI
;
Ping GONG
;
Fan SU
;
Jing LI
;
Zhiyi LIN
;
Yiming DONG
;
Danning ZHAO
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
COX-2,serum;
EGFR-TKI;
Prognosis
- From:
The Journal of Practical Medicine
2014;(23):3778-3781
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical value of expression levels of serum COX-2 in patients with advanced NSCLC before and after EGFR-TKI treatment. Methods The serum was collected from 58 cases. Before and after targeted therapy , the serum COX-2 level was examined by ELISA. Meanwhile , CT scan was exercised to evaluate the treatment. Follow-up interview was done. The relationship among the change in expression level of serum COX-2 , efficacy and PFS was analyzed. Results The serum COX-2 level significantly decreased in the response group (t = 11.258, P = 0.000) and increased in the PD group (t = -7.759, P =0.000) after EGFR-TKI treatment, and not significantly changed in the SD group (t = 1.424, P = 0.170). Before treatment, the baseline serum COX-2 level in the response group was significantly higher than that in the SD group and the PD group (F = 20.852, P = 0.000 ). Before the targeted therapy, the higher the level of serum COX-2 was, the longer PFS patients would enjoy. Conclusion Detection of the serum COX-2 contributes to the judgment of therapeutic effect of EGFR-TKI and can be used as a prediction of EGFR-TKI drugs outcomes for patients with advanced NSCLC.
